Department of Vascular Surgery, Erasmus University Medical Centre, Rotterdam, the Netherlands; Department of Surgery, Division of Vascular and Endovascular Surgery, Beth Israel Deaconess Medical Centre, Harvard Medical School, Boston, MA, USA.
Department of Vascular Surgery, Erasmus University Medical Centre, Rotterdam, the Netherlands.
Eur J Vasc Endovasc Surg. 2022 Dec;64(6):621-629. doi: 10.1016/j.ejvs.2022.08.024. Epub 2022 Aug 25.
Acute kidney injury (AKI) is a well known complication following cardiovascular procedures. The objective was to assess the incidence, risk factors, and prognostic significance of AKI after infrarenal endovascular aneurysm repair (EVAR) and complex EVAR (cEVAR; fenestrated or branched EVAR).
Consecutive patients undergoing elective infrarenal EVAR or cEVAR between 2000 and 2018 in two large teaching hospitals in the Netherlands were included. AKI was determined by serum creatinine levels increasing > 1.5 times or by an absolute increase of 26.5 mmol/L from baseline value (KDIGO criteria). The primary outcome was incidence of peri-operative AKI development. Secondary outcomes included mid-term renal function (RIFLE criteria), overall survival, and risk factors for AKI development. To determine survival and risk factors for AKI, multivariable Cox regression and logistic regression analyses were performed, accounting for pre-operative renal function and other confounders.
In total, 540 patients who underwent infrarenal EVAR with 147 patients who underwent cEVAR also included. The incidence of AKI was 8.7% (n = 47) in infrarenal EVAR patients and 23% (n = 34) in cEVAR patients (fenestrated EVAR 18%; branched EVAR 38%). In contrast to patients without AKI, the renal function of surviving patients with AKI remained significantly reduced at six weeks and did not return to pre-operative values following infrarenal EVAR (three year estimated glomerular filtration rate [eGFR] 59.3 ± 23.1 mL/min/1.73mvs. pre-operative eGFR 74.0 ± 21.7 mL/min/1.73m; p = .006) or following cEVAR (three year eGFR 52.0 ± 23.7 mL/min/1.73mvs. pre-operative eGFR 65.4 ± 18.6 mL/min/1.73m; p = .082). After risk adjusted analysis, compared with non-AKI, post-operative AKI development was associated with a higher three year mortality rate following both infrarenal and cEVAR (infrarenal EVAR mortality hazard ratio [HR 1.6, 95% confidence interval [CI] 1.01 - 2.7 [p = .046]; cEVAR mortality HR 2.4, 95% CI 1.1 - 5.2 [p = .033]). Following multivariable logistic regression, pre-operative chronic kidney disease (eGFR < 60 mL/min/1.73m; odds ratio [OR] 2.2, 95% CI 1.03 - 4.8) and neck diameter (OR 1.1, 95% CI 1.01 - 1.2) were significantly associated with AKI following infrarenal EVAR, whereas for cEVAR only contrast volume (OR 1.1, 95% CI 1.0 - 1.2]) was found to be statistically significantly associated with AKI.
AKI is a well described complication following infrarenal EVAR and is common after cEVAR. As AKI seems to be associated with permanent renal deterioration and lower survival, efforts to prevent AKI are essential. Future studies are required to assess what factors are associated with a higher risk of developing AKI following cEVAR.
急性肾损伤(AKI)是心血管手术后常见的并发症。本研究旨在评估肾下腔血管内修复术(EVAR)和复杂 EVAR(cEVAR;开窗或分支 EVAR)后 AKI 的发生率、危险因素和预后意义。
连续纳入 2000 年至 2018 年在荷兰两家大型教学医院接受选择性肾下腔 EVAR 或 cEVAR 的患者。通过血清肌酐水平升高>1.5 倍或基线值绝对值增加 26.5mmol/L(KDIGO 标准)来确定 AKI。主要结局为围手术期 AKI 发展的发生率。次要结局包括中期肾功能(RIFLE 标准)、总生存率和 AKI 发展的危险因素。为了确定生存和 AKI 的危险因素,进行了多变量 Cox 回归和逻辑回归分析,考虑了术前肾功能和其他混杂因素。
共纳入 540 例接受肾下腔 EVAR 的患者,其中 147 例接受 cEVAR。肾下腔 EVAR 患者 AKI 的发生率为 8.7%(n=47),cEVAR 患者为 23%(n=34)(开窗 EVAR 为 18%;分支 EVAR 为 38%)。与无 AKI 的患者相比,存活患者的肾功能在六周时仍明显降低,并且在肾下腔 EVAR 后(三年估计肾小球滤过率[eGFR]59.3±23.1mL/min/1.73mvs.术前 eGFR74.0±21.7mL/min/1.73m;p=0.006)或 cEVAR 后(三年 eGFR52.0±23.7mL/min/1.73mvs.术前 eGFR65.4±18.6mL/min/1.73m;p=0.082)未恢复到术前值。在风险调整分析后,与非 AKI 相比,术后 AKI 发展与肾下腔和 cEVAR 后更高的三年死亡率相关(肾下腔 EVAR 死亡率风险比[HR]1.6,95%置信区间[CI]1.01-2.7[ p=0.046];cEVAR 死亡率 HR2.4,95%CI1.1-5.2[p=0.033])。在多变量逻辑回归后,术前慢性肾脏病(eGFR <60mL/min/1.73m;比值比[OR]2.2,95%CI1.03-4.8)和颈部直径(OR1.1,95%CI1.01-1.2)与肾下腔 EVAR 后 AKI 显著相关,而对于 cEVAR,仅造影剂体积(OR1.1,95%CI1.0-1.2)与 AKI 有统计学显著相关。
AKI 是肾下腔 EVAR 后一种常见的并发症,在 cEVAR 后也很常见。由于 AKI 似乎与永久性肾损害和较低的生存率相关,因此努力预防 AKI 至关重要。需要进一步的研究来评估哪些因素与 cEVAR 后 AKI 发生风险较高相关。